Wakabayashi Nao, Nishioka Hiroshi, Yuzuriha Shunsuke
Department of Plastic and Reconstructive Surgery, Japanese Red Cross Society Nagano Hospital, Nagano, Japan.
Department of Plastic and Reconstructive Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Plast Reconstr Surg Glob Open. 2022 Feb 15;10(2):e4109. doi: 10.1097/GOX.0000000000004109. eCollection 2022 Feb.
Factor XIII (FXIII) is the final factor in the coagulation cascade. FXIII plays a critical role in clot stabilization by cross-linking fibrin and making the clot denser and stiffer. FXIII plays crucial roles in platelet clot retraction, wound healing, and tissue repair. When FXIII is deficient, unusual bleeding that persists for several days, delayed healing, and morbid granulation may occur. We present a case of acquired FXIII deficiency presenting as recurrent bleeding after head trauma. A 66-year-old man fell from a ladder and sustained a head injury. The patient had a history of postremission acute myeloid leukemia and Stanford type B aortic dissection and was on three antihypertensives but no antiplatelets or anticoagulants. Approximately 1 month postinjury, the patient suddenly experienced repeated bleeding and hematoma. Routine coagulation tests were normal; therefore, we suspected another type of coagulation disorder. Low FXIII activity was identified 39 days postinjury. We immediately administered concentrated human coagulation FXIII (Fibrogammin P). The patient's head contusion was completely healed by day 55 postinjury. Acquired FXIII deficiency should be considered when routine coagulation test results are normal. Plastic surgeons who treat injuries routinely must be cognizant of FXIII deficiency because the condition can be life-threatening and early detection is important. Whenever the process of wound healing is unusual or hematoma and bleeding recur unexpectedly with no clear explanation-despite suitable treatments-FXIII deficiency should be suspected and, if present, must be appropriately treated without delay.
凝血因子 XIII(FXIII)是凝血级联反应中的最后一个因子。FXIII 通过交联纤维蛋白使血凝块更致密、更坚硬,在血凝块稳定过程中发挥关键作用。FXIII 在血小板凝块回缩、伤口愈合和组织修复中也起着至关重要的作用。当 FXIII 缺乏时,可能会出现持续数天的异常出血、愈合延迟和病态肉芽组织。我们报告一例获得性 FXIII 缺乏症,表现为头部外伤后反复出血。一名 66 岁男性从梯子上跌落,头部受伤。该患者有缓解期急性髓系白血病和 B 型主动脉夹层病史,正在服用三种降压药,但未服用抗血小板药或抗凝药。受伤后约 1 个月,患者突然反复出现出血和血肿。常规凝血检查正常;因此,我们怀疑是另一种凝血障碍。受伤后 39 天发现 FXIII 活性降低。我们立即给予浓缩人凝血因子 XIII(纤维蛋白原复合物)。受伤后第 55 天,患者头部挫伤完全愈合。当常规凝血检查结果正常时,应考虑获得性 FXIII 缺乏症。经常治疗外伤的整形外科医生必须认识到 FXIII 缺乏症,因为这种情况可能危及生命,早期发现很重要。每当伤口愈合过程异常或血肿和出血在没有明确原因的情况下意外复发时——尽管进行了适当治疗——都应怀疑 FXIII 缺乏症,如果存在,必须立即进行适当治疗。